참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | Aniline | HCID 6115 | — |
| 반응물 | 4-Bromopyridine | HCID 14268 | — |
| 시약 | Sodium t-butoxide | HCID 23676156 | — |
| 촉매 | 1,1'-(9,9-Dimethyl-9H-xanthene-4,5-diyl)bis(1,1-diphenylphosphine) | HCID 636044 | — |
| 촉매 | Palladium (II) acetate | HCID 4144353 | — |
| 용매 | Toluene | HCID 1140 | — |
| 생성물 | N-phenylpyridin-4-amine | HCID 89945 | 24.88% |
반응 단계
ANILINE (3.94 mL, 43.29 mmol) was added to 4-bromopyridine (5.7 g, 36.08 mmol), PALLADIUM(II) ACETATE (0.162 g, 0.72 mmol), XANTPHOS (1.252 g, 2.16 mmol) and SODIUM TERT-BUTOXIDE (4.85 g, 50.51 mmol) in toluene (280 mL) under nitrogen. The resulting mixture was stirred at 100 °C for 4 hours. The reaction mixture was evaporated to dryness and redissolved in EtOAc (200 mL), and washed sequentially with water (2 x 100 mL) and saturated brine (100 mL). The organic layer was dried over MgSO4, filtered and preadsorbed onto silica. The crude product was purified by flash silica chromatography, elution gradient 0 to 100% EtOAc in heptane. Pure fractions were evaporated to dryness to afford N-phenylpyridin-4-amine (1.528 g, 24.88 %) as a pink solid.
출처 및 근거
| 출처 데이터셋 | 750 AstraZeneca ELN dataset |
|---|
| ORD ID | ord-72db1f71b9ee4c528872b1ba0810230a |
|---|
| 출처 메모 | 750 AstraZeneca ELN dataset |
|---|
